Back to Search
IRINA IACOBUCCI M.D.
M.D.
Family Medicine Physician
NPI: 1679990048IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
MD179390(OR)
Education
OTHER
Class of 2004
Research & Publications (20)
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).
PMID 19589926·Blood·2009
4-observational
Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method.
PMID 18838475·Haematologica·2008
8-other
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
PMID 18650450·Blood·2008
8-other
Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
PMID 19545285·Br J Haematol·2009
5-case
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
PMID 19211938·Blood·2009
3-trial
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
PMID 19188180·Clin Cancer Res·2009
3-trial
Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy.
PMID 19092801·Nat Clin Pract Oncol·2009
8-other
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.
PMID 19620627·J Exp Med·2009
7-preclinical
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
PMID 19589924·Blood·2009
4-observational
Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients.
PMID 18273047·Leukemia·2008
8-other
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
PMID 18165644·J Clin Oncol·2008
8-other
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
PMID 18367490·Haematologica·2008
3-trial
Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
PMID 18496498·Clin Adv Hematol Oncol·2008
6-review
Imatinib mesylate for the treatment of chronic myeloid leukemia.
PMID 18533795·Expert Rev Anticancer Ther·2008
6-review
Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies.
PMID 18824841·Acta Haematol·2008
8-other
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase.
PMID 18024412·Haematologica·2007
3-trial
Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio.
PMID 17339200·Haematologica·2007
8-other
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.
PMID 17488653·Haematologica·2007
8-other
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
PMID 17666373·Haematologica·2007
4-observational
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.
PMID 17229641·Haematologica·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via REBECCA T MORTON NONWEILER MD INC · 2 locations total
- Address
- 2865 DAGGETT AVE
KLAMATH FALLS, OR 97601 - Phone
- (541) 882-6311
Quick Facts
- NPI
- 1679990048
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 22
- Publications
- 20
Are you this provider?
Claim Your Profile